SCM
ONCE

Silvant Capital Management’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Silvant Capital Management’s Portfolio ONCE Stock Details ONCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-2,120
Closed -$241K – 343
2019
Q1 		$241K Hold
2,120
– – 0.04% 172
2018
Q4 		$83K Hold
2,120
– – 0.02% 235
2018
Q3 		$116K Hold
2,120
– – 0.01% 227
2018
Q2 		$175K Hold
2,120
– – 0.02% 207
2018
Q1 		$141K Buy
+2,120
New +$122K 0.02% 221

Other funds holding ONCE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Magnetar Financial
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
Pentwater Capital Management
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Silvant Capital Management's ONCE Position: Q2 2019 in Review

Silvant Capital Management sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q2 2019, closing a stake of 2,120 shares — an estimated $241K sold.

Silvant Capital Management first reported a position in ONCE in Q1 2018 and held it in 5 quarters. The position peaked at $241K in Q1 2019. 194 funds tracked by Wall St. Rank hold ONCE as of Q2 2019.

  • Silvant Capital Management reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Silvant Capital Management sold 2,120 Spark Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $241K.
  • Silvant Capital Management first reported a position in Spark Therapeutics, Inc. Common Stock in Q1 2018 and held it in 5 quarters.
  • Silvant Capital Management's Spark Therapeutics, Inc. Common Stock position peaked at $241K in Q1 2019.
  • 194 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q2 2019.

Based on Silvant Capital Management's 13F filing for Q2 2019, filed 9 Aug 2019.